Infection
Conditions
Interventions
PK model building group:Blood samples will be collected at the end of infusion, 4 to 6 hours after dose and the time before the next dose after continueouly dosing of 4 to 6 doses, in a total of three
Validation group:Blood samples will be collected 0.5 to 24 hours postdose,in a total of one to two samples.
Sponsors
Guangdong General Hospital (Guandong Academy of Medical Sciences)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Critically ill patients who are treated with tigecycline contineously 2. Male or female, aged at least 18 years; 3. Blood sampling could be conducted during the study; 4. Good cooperation and complience with the entire medical records.
Exclusion criteria
Exclusion criteria: 1. Patients who are alergic to tigecycline; 2. Patients whom the research doctors considered not suitable to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of tigecycline; | — |
Countries
China
Contacts
Public ContactChunbo Chen
Guangdong General Hospital (Guandong Academy of Medical Sciences)
Outcome results
None listed